Bucindolol
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethyl-ethyl]amino]propoxy]benzonitrile | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 71119-11-4 |
| ATC code | None |
| PubChem | CID 51045 |
| ChemSpider | 46266 |
| UNII | E9UO06K7CE |
| Chemical data | |
| Formula | C22H25N3O2 |
| Mol. mass | 363.45 g/mol |
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 .[1][3]
[edit] See also
[edit] References
- ^ a b "formularyjournal.modernmedicine.com". http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bucindolol-A-beta-blocker-for-the-treatment-of-hea/ArticleStandard/Article/detail/601855.
- ^ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology 56 (1): 30–6. PMID 9467185. http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=pha56030.
- ^ "FDA rejects bucindolol and questions trial integrity « CardioBrief". http://cardiobrief.org/2009/06/02/fda-rejects-bucindolol-and-questions-trial-integrity/.
|
| This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |

